Release
📈 Stocks
AbbVie Reports Positive Phase 1 Data for Metabolic Drug Candidate ABBV-295
(2 days ago)
AbbVie's ABBV-295 shows promising Phase 1 results with a long half-life, enabling potential bi-weekly dosing and strengthening the company's metabolic drug pipeline.